Your privacy, your choice

We use essential cookies to make sure the site can function. We also use optional cookies for advertising, personalisation of content, usage analysis, and social media.

By accepting optional cookies, you consent to the processing of your personal data - including transfers to third parties. Some third parties are outside of the European Economic Area, with varying standards of data protection.

See our privacy policy for more information on the use of your personal data.

for further information and to change your choices.
Skip to main content

Table 2 Comparison of cognitive function between the two groups

From: Effects of idebenone on cognitive function and serum biomarkers in patients with amnestic mild cognitive impairment

 

Control (0)

Control (6 m)

IDB (0)

IDB (6 m)

MMSE

23.19 ± 2.22

23.17 ± 1.93

23.38 ± 1.88

24.44 ± 1.34

MoCA

19.63 ± 2.23

18.9 ± 2.18

19.32 ± 2.18

20.96 ± 2.06*

  1. The data were presented as mean values and standard deviations. Control (0) represented the scores before treatment in the control group, Control (6 m) meant the scores observed in the control group after 6 months. IDB (0) represented the scores before treatment in the IDB treatment group, and IDB (6 m) represented the scores observed in the IDB treatment group after 6 months. There were no significant changes in MMSE and MoCA scores between the control group before and after treatment
  2. *means that there is a statistically significant difference in the IDB group after treatment compared to before treatment (P < 0.05)
Back to article page

European Journal of Medical Research

ISSN: 2047-783X

Contact us